Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind crossover study of S48168 (ARM210) versus placebo in adults with CPVT1
NL-OMON53588Phase 2Completed
- Sponsor
- RyCarma Therapeutics
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Surlorian in catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1) (2 arms), sponsored by RyCarma Therapeutics. Primary endpoint: Change in ectopy scoring scale from baseline to Day 28 versus placebo. Started Jun 2023; status: completed.
02
Drugs
Surlorian
03
Conditions
catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1)
Beyond the preview
Go deeper on NL-OMON53588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53588.